Institute of Urology, Lanzhou University Second Hospital, NO.82 Linxia Road, Chengguan District Lanzhou, Lanzhou, Gansu Province, 730030, PR China.
Gansu Province Clinical Research Center for urinary system disease, Lanzhou, Gansu Province, 730030, PR China.
Mol Biol Rep. 2024 Oct 22;51(1):1088. doi: 10.1007/s11033-024-10012-x.
As an AAA + ATPase, thyroid hormone receptor interacting protein 13 (TRIP13) primarily functions in DNA double-strand break repair, chromosome recombination, and cell cycle checkpoint regulation; aberrant expression of TRIP13 can result in chromosomal instability (CIN). According to recent research, TRIP13 is aberrantly expressed in a variety of cancers, and a patient's poor prognosis and tumor stage are strongly correlated with high expression of TRIP13. Tumor cell and subcutaneous xenograft growth can be markedly inhibited by TRIP13 knockdown or TRIP13 inhibitor administration. In the initiation and advancement of human malignancies, TRIP13 seems to function as an oncogene. Based on available data, TRIP13 may function as a biological target and biomarker for cancer. The creation of inhibitors that specifically target TRIP13 may present novel approaches to treating cancer.
作为一个 AAA+ATPase，甲状腺激素受体相互作用蛋白 13（TRIP13）主要在 DNA 双链断裂修复、染色体重组和细胞周期检查点调节中发挥作用；TRIP13 的异常表达会导致染色体不稳定（CIN）。最近的研究表明，TRIP13 在多种癌症中异常表达，患者的预后不良和肿瘤分期与 TRIP13 的高表达强烈相关。TRIP13 的敲低或 TRIP13 抑制剂的给药可以显著抑制肿瘤细胞和皮下异种移植的生长。在人类恶性肿瘤的发生和进展中，TRIP13 似乎作为一种癌基因发挥作用。基于现有数据，TRIP13 可能是癌症的生物靶标和生物标志物。开发特异性靶向 TRIP13 的抑制剂可能为癌症治疗提供新的方法。
